-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Immuneering, Maintains $11 Price Target

Benzinga·03/09/2026 09:52:00
Listen to the news
Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $11 price target.